The role of psychedelics in palliative care reconsidered: A case for psilocybin

J Psychopharmacol. 2016 Dec;30(12):1212-1214. doi: 10.1177/0269881116675781.

Authors

Benjamin Kelmendi^{1

2}, Philip Corlett^{2

3}, Mohini Ranganathan^{2

4

5}, Cyril D'Souza^{2

3

4

5}, John H Krystal^{6

2

3

7

4

5}

Affiliations

¹ Clinical Neuroscience Division, Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA ben.kelmendi@yale.edu.
² Departments of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
³ Departments of Neuroscience, Yale University School of Medicine, New Haven, CT, USA.
⁴ Schizophrenia and Neuropharmacology Research Group, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA.
⁵ Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.
⁶ Clinical Neuroscience Division, Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA.
⁷ Psychiatry Services, Yale-New Haven Hospital, New Haven, CT, USA.

PMID: 27909173
DOI: 10.1177/0269881116675781

No abstract available

Publication types

Comment

MeSH terms

Hallucinogens*
Humans
Palliative Care
Psilocybin*

Substances

Hallucinogens
Psilocybin